Mastocytosis, Indolent Systemic (DBCOND0158995)

Identifiers

Synonyms

Indolent Systemic Mastocytosis / Systemic mastocytosis / Indolent systemic mastocytosis (morphologic abnormality) / Indolent systemic mastocytosis (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Avapritinib	A selective tyrosine kinase inhibitor being investigated for the treatment of multidrug resistant gastrointestinal tumors.	Mast/stem cell growth factor receptor Kittarget ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 3A4enzyme Cytochrome P450 2C9enzyme Bile salt export pumptransporter Multidrug and toxin extrusion protein 1transporter Multidrug and toxin extrusion protein 2transporter Platelet-derived growth factor receptor alphatarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05923372	Evaluation of the DALY on a Cohort of Patients With Indolent Systemic Mastocytosis	No drug interventions	Not Available	Not Available	recruiting
NCT06210698	Angioedema Biomarker Research Study	No drug interventions	Not Available	Not Available	not_yet_recruiting
NCT00814073	Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis	Masitinib	treatment	3	completed
NCT03731260	(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis	Avapritinib	treatment	2	active_not_recruiting
NCT04333108	Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment	No drug interventions	treatment	3	recruiting
NCT03632811	Adaptation of the Questionnaire "Regarding Patient's Quality of Life With Mastocytosis" in the French Language	No drug interventions	Not Available	Not Available	completed
NCT02808793	A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK002	No drug interventions	treatment	1	completed
NCT04910685	(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis	No drug interventions	treatment	2 / 3	recruiting
NCT04655118	Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis	No drug interventions	treatment	2	recruiting
NCT02478957	Treatment of Indolent Systemic Mastocytosis With PA101	No drug interventions	treatment	2	completed
NCT03770273	Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis	No drug interventions	treatment	2	completed
NCT01920204	Midostaurin in Indolent Systemic Mastocytosis	No drug interventions	treatment	2	unknown_status